Epogen Sales Data
| Rank 23 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: May 2013 (updated quarterly).
The following data shows Epogen U.S. retail sales in Q1 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q1 2013 | 23 ( 3) |
$503,493 | -2.08% | 590 | -2.64% |
| Q4 2012 | 20 | $514,165 | -2.27% | 606 | -0.16% |
| Q3 2012 | 20 ( 2) |
$526,118 | -5.18% | 607 | -3.04% |
| Q2 2012 | 22 (5) |
$554,848 | 13.33% | 626 | 12.79% |
| Q1 2012 | 27 (7) |
$489,570 | -24.54% | 555 | -17.04% |
| Q4 2011 | 20 (2) |
$648,794 | 4.67% | 669 | 3.40% |
| Q3 2011 | 22 (2) |
$619,828 | -13.96% | 647 | -18.41% |
| Q2 2011 | 20 (1) |
$720,376 | 3.32% | 793 | 4.48% |
| Q1 2011 | 19 | $697,224 |  |
759 | |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
See Also
Related News
| Date | Article |
|---|---|
| June 24, 2011 | FDA Modifies Dosing Recommendations for Erythropoiesis-Stimulating Agents |
| October 19, 2010 | FDA Advisers Back Anemia Drugs for Kidney Patients |
| October 19, 2010 | FDA Panel Backs Anemia Drugs For Kidney Disease |
| February 16, 2010 | FDA Tightens Controls on Anemia Drugs |
| December 3, 2008 | FDA Issues Questions and Answers on Medication Guides for Erythropoiesis-stimulating Agents (ESAs). |
| November 24, 2008 | Study Calls for Greater Scrutiny of 'Off-Label' Drug Use |
| September 26, 2008 | Anemia Drugs Linked to Stroke Study Deaths: FDA |
